Vical Incorporated VICL
-
Vical's CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)
Vical Inc. ( VICL ) Bank of America Merrill Lynch 2013 Health Care Conference Call May 14 ..... out of New York. We are really excited today to be able to host Vical Incorporated . And without further adieu is my pleasure to introduce to you Vijay …
-
Vical's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Vical Incorporated ( VICL ) Q1 2013 Earnings Call Transcript May 9, 2013; 12:00 p ..... Presentation Operator Good day and welcome ladies and gentlemen to the Vical Incorporated , financial results conference cal. At this time I would like …
-
Notable earnings before Thursday’s open: [[AES]], [[AGU]], [[ALR]], [[AM]], [[AMRC]], [[APA]], [[BAM]], [[BCE]], [[CBB]], [[CNSL]], [[CTB]], [[CVC]], [[DF]], [[DISH]], [[DNDN]], [[GLP]], [[GTIV]], ...
… ALR , AM , AMRC , APA , BAM , BCE , CBB , CNSL , CTB , CVC , DF , DISH , DNDN , GLP , GTIV , IRC , KEM , KIOR , MEA , NPSP , OWW , PCP , SNE , SNSS , SPH , SRPT , TK , TNK , VICL , VNDA , WAC , WFR , WIN , WWAV , XRAY Post your comment!
-
Vical ( VICL ) says the addition of its Vaxfectin adjuvant to Baxter's (BAX) influenza vaccines "substantially increases both antibody and T-cell responses." VICL's VP of vaccine research says seasonal ...
Vical ( VICL ) says the addition of its Vaxfectin adjuvant to Baxter's ( BAX ) influenza vaccines "substantially increases both antibody and T-cell responses." VICL 's VP of vaccine research says seasonal influenza vaccines sometimes underperform …
-
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
By PropThink: By Dee Kotak, MD Vical Incorporated ( VICL ) expects to announce top-line data mid-2013 from the pivotal Phase III trial ( NCT00395070 ) of Allovectin in metastatic melanoma …
-
Notable earnings before Wednesday’ s open: [[AB]], [[ADT]], [[AFAM]], [[AFSI]], [[AGN]], [[AH]], [[AMT]], [[ARW]], [[AVA]], [[CCJ]], [[CHK]], [[CLH]], [[CLX]], [[CMCSA]], [[CVH]], [[CVS]], [[DLPH]], ...
… CVS , DLPH , DVN , ENR , EXAS , EXC , GRMN , GWR , H , HSP , HUM , ICE , IPGP , IQNT , IRM , JRCC , KCG , KFN , MA , MKL , MRK , NVO , PDCE , PKD , POR , PSX , RDC , RDN , SEE , SPW , TLM , TWX , VG , VIAB , VICL , VPHM Post your comment!
-
Notable earnings before Wednesday’ s open: [[AB]], [[ADT]], [[AFAM]], [[AFSI]], [[AGN]], [[AH]], [[AMT]], [[ARW]], [[AVA]], [[CCJ]], [[CHK]], [[CLH]], [[CLX]], [[CMCSA]], [[CVH]], [[CVS]], [[DLPH]], ...
… CVS , DLPH , DVN , ENR , EXAS , EXC , GRMN , GWR , H , HSP , HUM , ICE , IPGP , IQNT , IRM , JRCC , KCG , KFN , MA , MKL , MRK , NVO , PDCE , PKD , POR , PSX , RDC , RDN , SEE , SPW , TLM , TWX , VG , VIAB , VICL , VPHM Post your comment!
-
A Tale Of Three Pharmaceuticals: Getting Exciting In 2013
By Chemistfrog : Development phase pharmaceutical companies offer investors a unique combination of risk and reward. Very few sectors can offer the potential of gains of many hundreds of percents, while having an even greater chance at failure with one-day losses over 80% being commonplace. ...
-
Melanoma: Battle Of 3 Cancer Vaccines
… John Hodge : In the last five years, shares of Vical Incorporated ( VICL ) have traded near flat. This breakeven return ..... question: With a $350 million market cap, will Vical Incorporated become Celldex Therapeutics ( CLDX ) or Oncothyreon …
-
Companies Focused On Cancers Of The Epidermal Layers May Yield Profits
By Premier Penny Stocks : When surgery is not an option with cancer doctors must turn to targeted delivery platforms to deliver the much needed cancer drugs. With cancer continuing to be one of the leading causes of death in the U.S., the need for novel cancer therapies will only increase. In this